- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04231812
First In Human Study Evaluating the Safety and Performance of the "LapBox" Containment System for Laparoscopic Tissue Morcellation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The LapBox is intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy Ten (10) adult female patients, scheduled for the laparoscopic gynecological procedure, with up to 700gr mass to be removed and with no suspicion of malignancy.
Patients scheduled for elective laparoscopic hysterectomy, myomectomy or removal of an adnexal mass where either manual morcellation or power morcellation is needed for tissue will be enrolled. Each patient will be required to participate in 3 visits:
Visit 1: Screening and Enrollment, as part of the pre-operative visit and confirmation of compliance. Such a visit can be more than 1 day.
Visit 2: Laparoscopic organ removal procedure- morcellation utilizing LapBox containment system.
Visit 3:up appointment up to 7 weeks (7 days) post-procedure.
During visit 2 (laparoscopic organ removal procedure), the following steps will be performed:
- Following tissue harvest and prior to morcellation, a peritoneal wash sample will be obtained for a cytology evaluation.
- The LapBox will then be inserted to the patient abdomen through the abdominal wall and deployed.
- The harvested tissue will be inserted into the LapBox using standard technique.
- The LapBox opening will be extracted outside the abdomen.
- Depending on the type of morcellation (power or mechanical), the incision may be extended as needed.
- The appropriate type of port will be placed.
Power morcellation:
- The morcellator will be inserted.
- The laparoscope will be placed inside the bag and provide visualization of the procedure. Alternatively, direct visualization may be utilized.
- The morcellator will be operated in a standardized fashion. Manual morcellation will be performed as per standard practice.
- The LapBox will be removed through the abdominal opening. A second peritoneal wash sample will be obtained for a cytology evaluation in order to compare pre and post morcellation findings.
Following the procedure, tissue weight will be recorded, and leakage testing will be performed on used devices.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stav Tori
- Phone Number: 972523594441
- Email: stav@ark-surgical.com
Study Contact Backup
- Name: Ilana Fishman
- Phone Number: 972547545065
- Email: ilana@endpoint.co.il
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients indicated for elective surgery requiring laparoscopic hysterectomy, myomectomy where either manual morcellation or power morcellation is needed for tissue removal at which a morcellator for cutting and extraction of tissue is required.
- Pre- menopausal woman patient age 18-50 years
- Mass measured with diameter up to 10 cm to be removed
- Normal Pap test result within the last 24 months prior to enrollment
- Normal and /or Non-Clinically Significant as per investigator discretion CBC and Blood chemistry test within at least 6 months prior to surgery.
- Signed an informed consent
Exclusion Criteria:
- Emergency cases
- Abdominal wall thickness is greater than 10 cm according to US measurements.
- Patient requires procedure involving the ovaries (e.g., Oophorectomy, Salpingo)
- Patient is defined as a "high risk" patient for developing cancer (per standard assessment, including but not limited to imaging)
- Suspicion of malignant or pre-malignant tissue according to preoperative assessment including US exam within 30 days prior to surgery
- Known or suspected gynecologic malignancy within the past five years
- Pacemaker, internal defibrillator/cardio converter
- Previous extensive pelvic surgery or any other medical procedure which in the investigator's judgment contraindicates the patient's participation
- Contraindications to anesthesia or abdominal surgery. ASA score above 3
- Concurrent participation in any other clinical study
- Active infection at the time of the procedure.
- BMI<20 or BMI>40
- Known history or presence of any medical disorder, which in the investigator's judgment contraindicates the patient's participation (e.g., Known and documented active liver disease, renal failure, cognitive disorder, cardiopulmonary disease, impaired coagulation parameters, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DEVICE_FEASIBILITY
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: open lable
Prospective, open-label
|
The "LapBox" is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Related Adverse Events Occurrence
Time Frame: through study procedure, up to 10 weeks from procedure
|
Occurrence of device use related adverse events as documented and reported, under DSMB review
|
through study procedure, up to 10 weeks from procedure
|
Device Performance and Integrity
Time Frame: following completion of procedure and study device use (1 day)
|
Leak testing will be performed following the each procedure to confirm device integrity. Used device will be filled with color fluid to provide clear identification of possible leakage. Test will performed by Investigator delegated study team member and results will be documented in CRF. |
following completion of procedure and study device use (1 day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device performance
Time Frame: up to 10 weeks following the procedure
|
Comparison of the presence of cancerous cells pre and post morcellation via peritoneal wash sample cytology
|
up to 10 weeks following the procedure
|
Device Performance (usability)
Time Frame: following completion of procedure and study devise use (1 day)
|
Ease of use of the device (usability evaluation via questionnaire).
|
following completion of procedure and study devise use (1 day)
|
Device Performance
Time Frame: through study procedure, up to 10 weeks from procedure
|
Intra- or post-operative complications, Adverse Events and Device Related Adverse Events
|
through study procedure, up to 10 weeks from procedure
|
Device Performance
Time Frame: following completion of procedure and study device use (1 day)
|
Procedure time
|
following completion of procedure and study device use (1 day)
|
Device Performance
Time Frame: up to 10 weeks following the procedure
|
Hospitalization length
|
up to 10 weeks following the procedure
|
Device Performance
Time Frame: following completion of procedure and study devise use (1 day)
|
Specimen (removed tissue) weight collection
|
following completion of procedure and study devise use (1 day)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roy Mashiach, Dr, Assuta Tel Aviv Medical Center, Tel Aviv, Israel
- Principal Investigator: Yuval Kaufman, Dr, Assuta Haifa Medical Center, Haifa, Israel
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ARK-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laparoscopic Surgical Procedure
-
Zagazig UniversityCompletedLaparoscopic Surgery | Safety Issues | Insufflation | Operative Surgical ProcedureEgypt
-
Danderyd HospitalCompletedNerve Block | Laparoscopic Surgical ProcedureSweden
-
Taipei Veterans General Hospital, TaiwanDuke UniversityUnknownHemodynamic Monitoring | Anesthesia and Analgesia | Monitoring, Physiologic | Intraoperative Neurophysiological Monitoring | Laparoscopic Surgical ProcedureTaiwan
-
Duke UniversityVirtual PortsWithdrawnLaparoscopic Sleeve Gastrectomy | Minimally Invasive Surgical Procedure | Laparoscopic Gastric Banding | Laparoscopic Roux-en-Y Gastric Bypass | Laparoscopic Fundoplication Procedure | Laparoscopic Heller Myotomy | Laparoscopic Paraesophageal Hernia Repair | Laparoscopic Gastric ResectionUnited States
-
Ankara UniversityCompletedObesity | Surgery--Complications | Laparoscopic Surgical Procedure
-
University of Texas Southwestern Medical CenterThe University of Texas Health Science Center, Houston; University of Alabama... and other collaboratorsCompletedSurgical Procedure, Unspecified | Surgical SimulationUnited States
-
3MCompletedSurgical Procedure, Unspecified | Surgical Skin PreparationRomania
-
Margherita CADDEDUSt. Joseph's Healthcare Hamilton; McMaster University; The Physicians' Services...Unknown
-
Zealand University HospitalRecruiting
-
Hospital del MarRecruitingSurgical Procedure, UnspecifiedSpain
Clinical Trials on Laparoscopic Tissue Morcellation working space (bag)
-
Hospices Civils de LyonCompletedLaparoscopy | Uterine Myomatosis | Hysterectomy, VaginalFrance